loadpatents
Patent applications and USPTO patent grants for MURR; Ramona.The latest application filed is for "combination therapy of tumor targeted icos agonists with t-cell bispecific molecules".
Patent | Date |
---|---|
Combination Therapy Of Tumor Targeted Icos Agonists With T-cell Bispecific Molecules App 20200306373 - BACAC; Marina ;   et al. | 2020-10-01 |
Bispecific Antibodies Against Cd3epsilon And Ror1 App 20200255521 - Kind Code | 2020-08-13 |
Bispecific antibodies against CD3 and BCMA Grant 10,253,104 - Vu , et al. | 2019-04-09 |
Bispecific Antibodies Against Cd3epsilon And Bcma App 20170306036 - VU; Minh Diem ;   et al. | 2017-10-26 |
Bispecific Antibodies Against Cd3epsilon And Ror1 App 20170306018 - VU; MINH DIEM ;   et al. | 2017-10-26 |
Bispecific Antibodies Against Cd3epsilon And Ror1 For Use In The Treatment Of Ovarian Cancer App 20170306044 - VU; MINH DIEM ;   et al. | 2017-10-26 |
BISPECIFIC ANTIBODIES AGAINST CD3EPSILON and ROR1 App 20160297881 - VU; Minh Diem ;   et al. | 2016-10-13 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.